CB 001

Drug Profile

CB 001

Alternative Names: CB-001

Latest Information Update: 13 Feb 2007

Price : $50

At a glance

  • Originator ViaCell
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 13 Feb 2007 Clinical data added to the adverse events and Cancer pharmacodynamics sections
  • 07 Feb 2007 Discontinued - Phase-I/II for Haematological malignancies in USA (Infusion)
  • 19 Dec 2005 The US FDA has lifted the clinical hold on ViaCell's phase I/II trial of CB 001
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top